CD19 and CD22 targeted CAR-T cell therapy (Chongqing Xinqiao Hospital)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameCD19 and CD22 targeted CAR-T cell therapy (Chongqing Xinqiao Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsLymphoma, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaPending

Originator CompaniesThe Second Affiliated Hospital of Army Medical University

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe Second Affiliated Hospital of Army Medical University

Active IndicationsN/A

Inactive IndicationsLymphoma, B-Cell

Other Information

ATC CodeN/A